Ftse Mib
33.313,14
0,05%
DAX
19.243,69
0,50%
S&P 500
5.948,71
0,00%
NASDAQ
18.972,42
0,00%
Bitcoin
97.762,75
-0,76%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cue Biopharma Inc (CUE) Cue Biopharma Inc (CUE) Notizie

CUE

Cue Biopharma (CUE)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CUE
DataOraFonteTitoloSimboloCompagnia
14/11/202422:05GlobeNewswire Inc.Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CUECue Biopharma Inc
14/11/202422:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CUECue Biopharma Inc
14/11/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CUECue Biopharma Inc
14/11/202414:00GlobeNewswire Inc.Cue Biopharma Announces Strategic Organizational TransitionNASDAQ:CUECue Biopharma Inc
12/11/202414:00GlobeNewswire Inc.Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare ConferenceNASDAQ:CUECue Biopharma Inc
08/11/202419:30GlobeNewswire Inc.Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual MeetingNASDAQ:CUECue Biopharma Inc
07/10/202423:07Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:CUECue Biopharma Inc
04/10/202415:00GlobeNewswire Inc.Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNASDAQ:CUECue Biopharma Inc
27/09/202422:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CUECue Biopharma Inc
27/09/202405:26GlobeNewswire Inc.Cue Biopharma Announces Pricing of $12.0 Million Public OfferingNASDAQ:CUECue Biopharma Inc
27/09/202405:10GlobeNewswire Inc.Cue Biopharma Announces Proposed Public OfferingNASDAQ:CUECue Biopharma Inc
10/09/202422:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CUECue Biopharma Inc
09/09/202414:00GlobeNewswire Inc.Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business OfficerNASDAQ:CUECue Biopharma Inc
05/09/202422:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CUECue Biopharma Inc
05/09/202422:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CUECue Biopharma Inc
03/09/202414:00GlobeNewswire Inc.Cue Biopharma to Present at The Promise of Interleukin-2 Therapy ConferenceNASDAQ:CUECue Biopharma Inc
28/08/202422:00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:CUECue Biopharma Inc
19/08/202422:05GlobeNewswire Inc.Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CUECue Biopharma Inc
13/08/202414:00GlobeNewswire Inc.Cue Biopharma to Host Business Update Call and WebcastNASDAQ:CUECue Biopharma Inc
25/07/202422:05GlobeNewswire Inc.Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital RequirementsNASDAQ:CUECue Biopharma Inc
04/06/202414:00GlobeNewswire Inc.Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual MeetingNASDAQ:CUECue Biopharma Inc
03/06/202414:00GlobeNewswire Inc.Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024NASDAQ:CUECue Biopharma Inc
24/05/202422:00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CUECue Biopharma Inc
09/05/202422:05GlobeNewswire Inc.Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CUECue Biopharma Inc
08/05/202414:00GlobeNewswire Inc.Cue Biopharma to Present at the 20th Annual PEGS Boston SummitNASDAQ:CUECue Biopharma Inc
07/05/202414:00GlobeNewswire Inc.Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences ConferenceNASDAQ:CUECue Biopharma Inc
24/04/202416:01GlobeNewswire Inc.Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:CUECue Biopharma Inc
08/04/202422:05GlobeNewswire Inc.Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business HighlightsNASDAQ:CUECue Biopharma Inc
29/02/202416:00GlobeNewswire Inc.Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers SymposiumNASDAQ:CUECue Biopharma Inc
06/02/202414:00GlobeNewswire Inc.Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:CUECue Biopharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CUE

La tua Cronologia

USOTC
PHIXF
Phase Holographic Imagin... (QB)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network